2 terminated. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 3 | 2 | Terminated 2 |
Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab ranibizumab - Age-Related Macular Degeneration | Phase 2 / Phase 3 | Terminated | University of California, San Diego | 20 | 2011-07-01 | 2019-08-28 |
| Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) Verteporfin Photodynamic Therapy, Ranibizumab, Placebo - Macular Degeneration, Choroidal Neovascularization | Phase 2 / Phase 3 | Terminated | Novartis | 255 | 2007-05-01 | 2011-04-21 |
Choroidal Neovascularization (2) · Macular Degeneration (2)
Novartis (1) · University of California, San Diego (1)
Austria (1) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1) · United Kingdom (1) · United States (1)